The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 17, 2011
Filed:
Jul. 10, 2006
Shelia M. Violette, Lexington, MA (US);
Louise A. Koopman, Brookline, MA (US);
Kenneth J. Simon, Cambridge, MA (US);
Paul H. Weinreb, Andover, MA (US);
Herman W. T. Van Vlijmen, Mechelen, BE;
Jose W. Saldanha, Endfield, GB;
Alexey A. Lugovskoy, Woburn, MA (US);
Shelia M. Violette, Lexington, MA (US);
Louise A. Koopman, Brookline, MA (US);
Kenneth J. Simon, Cambridge, MA (US);
Paul H. Weinreb, Andover, MA (US);
Herman W. T. van Vlijmen, Mechelen, BE;
Jose W. Saldanha, Endfield, GB;
Alexey A. Lugovskoy, Woburn, MA (US);
Biogen Idec MA Inc., Cambridge, MA (US);
Abstract
The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αβintegrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of such antibodies, pharmaceutical compositions comprising them, and methods of treating, diagnosing and/or preventing various diseases and disorders by administering the humanized anti-αβantibodies of the invention. The invention also relates to the identification of differential expression of the integrin αβon the surfaces of tumor cells and tissues, the use of this differential expression in determining the metastatic potential of tumor cells, and methods of diagnosis and treatment/prevention of tumor metastasis and for elimination of residual metastatic tumor cells using ligands, particularly antibodies, that bind to integrin αβ.